Polar Asset Management Partners Inc. Grows Stock Holdings in Sanofi $SNY

Key Points

• Polar Asset Management Partners Inc. increased its holdings in Sanofi by 105.5%, acquiring an additional 33,138 shares during the first quarter, bringing its total ownership to 64,538 shares valued at approximately $3,579,000.
• Sanofi's stock opened at $46.50 with a market cap of $114.18 billion, experiencing a price fluctuation between a 12-month low of $44.73 and a high of $60.12.
• In its latest quarterly earnings report, Sanofi missed earnings expectations with an EPS of $0.90, while revenue was reported at $11.34 billion, exceeding analyst estimates.

Polar Asset Management Partners Inc. boosted its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 105.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,538 shares of the company's stock after purchasing an additional 33,138 shares during the period. Polar Asset Management Partners Inc.'s holdings in Sanofi were worth $3,579,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of SNY. NewEdge Advisors LLC lifted its stake in shares of Sanofi by 1.7% in the 1st quarter. NewEdge Advisors LLC now owns 37,438 shares of the company's stock valued at $2,076,000 after purchasing an additional 642 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Sanofi by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company's stock worth $2,732,000 after acquiring an additional 752 shares during the period. Banque Transatlantique SA purchased a new stake in shares of Sanofi during the 1st quarter worth $33,000. AQR Capital Management LLC raised its stake in shares of Sanofi by 107.2% during the 1st quarter. AQR Capital Management LLC now owns 30,518 shares of the company's stock worth $1,693,000 after buying an additional 15,791 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its stake in Sanofi by 5.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 504,671 shares of the company's stock valued at $27,989,000 after buying an additional 24,255 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SNY shares. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Barclays reissued an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Morgan Stanley raised shares of Sanofi from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $56.00 to $58.00 in a research report on Monday. Finally, Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $62.67.

Sanofi Stock Up 1.4%

NASDAQ:SNY traded up $0.65 during trading hours on Tuesday, reaching $47.45. The company had a trading volume of 2,431,668 shares, compared to its average volume of 2,607,123. The firm has a market cap of $116.51 billion, a price-to-earnings ratio of 11.39, a P/E/G ratio of 1.11 and a beta of 0.51. The business's 50-day simple moving average is $48.78 and its two-hundred day simple moving average is $51.31. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company had revenue of $11.34 billion during the quarter, compared to analysts' expectations of $9.91 billion. During the same quarter in the previous year, the firm earned $1.73 earnings per share. The firm's revenue was down 7.0% compared to the same quarter last year. On average, equities analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.